Cyclopamine Biosynthesis via Sf9 Cell Intermediary
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The current supply of cyclopamine, a potent Hedgehog signaling pathway inhibitor with potential as a cancer therapeutic, is limited due to complex chemical synthesis and reliance on wild-collected Veratrum californicum, which is not easily cultivable, necessitating a method for enhanced in planta production.
Innovation Solution
A biosynthetic gene discovery method correlating cyclopamine accumulation with RNAseq gene expression data to identify and engineer the cyclopamine biosynthetic pathway into an easily cultivable host plant, facilitating sustainable and economic production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If cyclopamine is produced through complex chemical synthesis or wild collection, then the compound can be obtained, but the production cost is high and supply is limited
Solution Approach 1:
The patent uses Spodoptera frugiperda Sf9 cells as a biological intermediary system to produce cyclopamine. The Sf9 cells are engineered to express the cyclopamine biosynthetic pathway enzymes, serving as a living factory that converts simple precursors into the complex cyclopamine molecule, thereby replacing complex chemical synthesis with a more efficient biological production system
Solution Approach 2:
The patent enables the Sf9 cell system to self-produce cyclopamine through the engineered biosynthetic pathway. The cells autonomously carry out the multi-step enzymatic reactions required to synthesize cyclopamine from available precursors, eliminating the need for complex external chemical synthesis interventions and enabling sustainable, scalable production
2Quantity of substance
If Veratrum californicum is wild-collected, then cyclopamine can be extracted, but the plant is not easily cultivable and growth is slow
Solution Approach 1:
The patent transfers the cyclopamine biosynthetic pathway from the slow-growing Veratrum californicum plant to the rapidly proliferating Sf9 cell system. The Sf9 cells serve as an intermediary production platform that can be cultured quickly and scaled up, thereby decoupling cyclopamine production from the constraints of plant growth rate and cultivability
Solution Approach 2:
The patent creates a cellular copy of the cyclopamine biosynthetic pathway by engineering Sf9 cells to express the necessary enzymes. This cellular model system replicates the plant's metabolic capability without requiring the actual plant, enabling production in a more controllable and scalable system
3Productivity
If the cyclopamine biosynthetic pathway is engineered into a host plant, then sustainable production is achieved, but knowledge of the underlying biosynthetic genes is currently lacking
Solution Approach 1:
The patent employs RNAseq gene expression analysis to identify and characterize the biosynthetic genes involved in cyclopamine production. By correlating gene expression data with cyclopamine accumulation, the researchers gain feedback information about which genes are critical for the pathway, enabling targeted engineering of the biosynthetic pathway in host systems
Solution Approach 2:
The patent replaces the need for extensive trial-and-error genetic engineering by using computational bioinformatics approaches. RNAseq data and bioinformatic analysis substitute for mechanical gene-by-gene characterization methods, rapidly identifying candidate biosynthetic genes and enabling more efficient pathway engineering
Data Source
AI summary
The present disclosure relates generally to the identification of enzymes within the cyclopamine biosynthesis pathway as well as to engineering transgenic plants or organisms for the production of cyclopamine.